BioMS Medical

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), for the treatment of multiple sclerosis, is currently being evaluated in two pivotal Phase III clinical trials for secondary progressive MS patients: MAESTRO-01 in Canada and Europe, and MAESTRO-03 in the United States. Additionally, it is being assessed in a Phase II clinical trial in Europe for relapsing-remitting MS patients, named MINDSET-01.